ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pearl, J. M.
Right arrow Articles by Nelson, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pearl, J. M.
Right arrow Articles by Nelson, D. P.

Ann Thorac Surg 1999;68:1714-1721
© 1999 The Society of Thoracic Surgeons

Original Articles

Bosentan prevents hypoxia-reoxygenation–induced pulmonary hypertension and improves pulmonary function

Jeffrey M. Pearl, MDa, Scott A. Wellmann, MDa, Jerri L. McNamara, CCPa, John P. Lombardi, CCPa, Connie J. Wagner, BSa, Jenni L. Raake, RRTa, David P. Nelson, MDa

a Division of Pediatric Cardiothoracic Surgery, Children’s Hospital Medical Center, Cincinnati, Ohio, USA

Address reprint requests to Dr Pearl, Division of Cardiothoracic Surgery, Children’s Hospital Medical Center, 3333 Burnet Ave, OSB-3, Cincinnati, OH 45229
e-mail: pearj0{at}chmcc.org

Presented at the Thirty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, Jan 25–27, 1999.

Background. Acute hypoxia results in increased pulmonary vascular resistance. Despite reoxygenation, pulmonary vascular resistance remains elevated and pulmonary function is altered. Endothelin-1 might contribute to hypoxia-reoxygenation–induced pulmonary hypertension and to reoxygenation injury by stimulating leukocytes. This study was carried out using an established model of hypoxia and reoxygenation to determine whether endothelin-1 blockade with Bosentan could prevent hypoxia-reoxygenation–induced pulmonary hypertension and reoxygenation injury.

Methods. Twenty neonatal piglets underwent 90 minutes of hypoxia, 60 minutes of reoxygenation on cardiopulmonary bypass, and 2 hours of recovery. Control animals (n = 12) received no drug treatment, whereas the treatment group (n = 8) received the endothelin-1 receptor antagonist, Bosentan, throughout hypoxia.

Results. In controls, pulmonary vascular resistance increased during hypoxia to 491% of baseline and remained elevated after reoxygenation; however in the Bosentan group, it increased to only 160% of baseline by end-hypoxia, then decreased to 76% at end-recovery. Arterial endothelin-1 levels in controls increased to 591% of baseline after reoxygenation. Arterial nitrite levels decreased during hypoxia in controls but were maintained in the Bosentan group. Consequently, animals in the Bosentan group had better postreoxygenation pulmonary vascular resistance, A-a gradient, and airway resistance along with lower myeloperoxidase levels than controls.

Conclusions. Acute hypoxia and postreoxygenation pulmonary hypertension was attenuated by Bosentan, which maintained nitric oxide levels during hypoxia, decreased leukocyte-mediated injury, and improved pulmonary function.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Cell Physiol.Home page
A. Rivera
Reduced sickle erythrocyte dehydration in vivo by endothelin-1 receptor antagonists
Am J Physiol Cell Physiol, September 1, 2007; 293(3): C960 - C966.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
J. Dupuis
Endothelin: setting the scene in PAH
Eur. Respir. Rev., August 1, 2007; 16(102): 3 - 7.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
T. Higenbottam
Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease: A Case for Treatment
Proceedings of the ATS, April 1, 2005; 2(1): 12 - 19.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin
Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines
Chest, July 1, 2004; 126(1_suppl): 35S - 62S.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. M. Pearl, S. M. Schwartz, D. P. Nelson, C. J. Wagner, J. M. Lyons, S. M. Bauer, and J. Y. Duffy
Preoperative glucocorticoids decrease pulmonary hypertension in piglets after cardiopulmonary bypass and circulatory arrest
Ann. Thorac. Surg., March 1, 2004; 77(3): 994 - 1000.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Sharma
Treatment of Pulmonary Arterial Hypertension: A Step Forward
Chest, July 1, 2003; 124(1): 8 - 11.
[Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
A. V Agapitov and W. G Haynes
Role of endothelin in cardiovascular disease
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1): 1 - 15.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. M. Pearl, D. P. Nelson, C. J. Wagner, J. P. Lombardi, and J. Y. Duffy
Endothelin receptor blockade reduces ventricular dysfunction and injury after reoxygenation
Ann. Thorac. Surg., August 1, 2001; 72(2): 565 - 570.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
J. M. Pearl, D. P. Nelson, S. A. Wellmann, J. L. Raake, C. J. Wagner, J. L. McNamara, and J. Y. Duffy
Acute hypoxia and reoxygenation impairs exhaled nitric oxide release and pulmonary mechanics
J. Thorac. Cardiovasc. Surg., May 1, 2000; 119(5): 931 - 938.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1999 by The Society of Thoracic Surgeons.